ESC Congress 2025 - REBOOT-MI finds that beta-blocker therapy after MI did not reduce the occurrence of adverse events in patients with LVEF greater than 40%.

Dr Borja Ibanez (National Centre for Cardiovascular Research, Madrid, ES) joins us to discuss findings from REBOOT-CNIC (NCT03596385). The prospective, randomised, open-label trial investigated the benefits of long-term betablocker therapy in patients without a history of heart failure who have been discharged after an acute myocardial infarction (MI) with a left ventricular ejection fraction (LVEF) greater than 40%. The primary outcome measure is five years incidence of all cause mortality, reinfarction, and heart failure admission.

Findings showed a similar incidence of all-cause death, reinfarction or heart failure admission with beta-blockers as compared to patients who did not recieve beta-blocker therapy. Despite this, results from patients with mildly reduced LVEF (40-49%) when combined with data from other trials suggests there could be benefit in this subgroup.

Interview Questions:

1. What is the background behind the REBOOT-CNIC trial?
2. What was the study design and patient population?
3. What are the key outcomes?
4. What are the take-home messages for practice?
5. What are the next steps, and are there specific patient populations who might benefit from additional research on this topic?

Recorded on-site at ESC Congress 2025, Madrid.

Editors: Jordan Rance, Yazmin Sadik.
Video Specialists: Dan Brent, Tom Green, Mike Knight, Oliver Miles, David Ben-Harosh.

Support: This is an independent interview produced by Radcliffe Cardiology.